<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:51:30Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3888952" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3888952</identifier><datestamp>2014-01-22</datestamp><setSpec>frontonco</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2234-943X</issn>
      <publisher>
        <publisher-name>Frontiers Media S.A.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3888952</article-id>
      <article-id pub-id-type="pmcid">PMC3888952</article-id>
      <article-id pub-id-type="pmc-uid">3888952</article-id>
      <article-id pub-id-type="pmid">24455489</article-id>
      <article-id pub-id-type="doi">10.3389/fonc.2013.00333</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Oncology</subject>
          <subj-group>
            <subject>Original Research</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Evidence That <italic>GRIN2A</italic> Mutations in Melanoma Correlate with Decreased Survival</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Dâmello</surname>
            <given-names>Stacey Ann N.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/130462"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Flanagan</surname>
            <given-names>Jack U.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/130704"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Green</surname>
            <given-names>Taryn N.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leung</surname>
            <given-names>Euphemia Y.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/70335"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Askarian-Amiri</surname>
            <given-names>Marjan E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/69375"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Joseph</surname>
            <given-names>Wayne R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McCrystal</surname>
            <given-names>Michael R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Isaacs</surname>
            <given-names>Richard J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shaw</surname>
            <given-names>James H. F.</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Furneaux</surname>
            <given-names>Christopher E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>During</surname>
            <given-names>Matthew J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">
            <sup>9</sup>
          </xref>
          <xref ref-type="aff" rid="aff10">
            <sup>10</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Finlay</surname>
            <given-names>Graeme J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/89562"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baguley</surname>
            <given-names>Bruce C.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/36037"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kalev-Zylinska</surname>
            <given-names>Maggie L.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff11">
            <sup>11</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
          <uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/120240"/>
        </contrib>
      </contrib-group>
      <aff id="aff1"><sup>1</sup><institution>Department of Molecular Medicine and Pathology, School of Medical Sciences, University of Auckland</institution>, <addr-line>Auckland</addr-line>, <country>New Zealand</country></aff>
      <aff id="aff2"><sup>2</sup><institution>Auckland Cancer Society Research Centre, University of Auckland</institution>, <addr-line>Auckland</addr-line>, <country>New Zealand</country></aff>
      <aff id="aff3"><sup>3</sup><institution>Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland</institution>, <addr-line>Auckland</addr-line>, <country>New Zealand</country></aff>
      <aff id="aff4"><sup>4</sup><institution>Department of Clinical Oncology, Auckland District Health Board</institution>, <addr-line>Auckland</addr-line>, <country>New Zealand</country></aff>
      <aff id="aff5"><sup>5</sup><institution>Canopy Cancer Care, Mercy Hospital</institution>, <addr-line>Auckland</addr-line>, <country>New Zealand</country></aff>
      <aff id="aff6"><sup>6</sup><institution>Regional Cancer Treatment Service, Palmerston North Public Hospital</institution>, <addr-line>Palmerston North</addr-line>, <country>New Zealand</country></aff>
      <aff id="aff7"><sup>7</sup><institution>Oncology Surgery Ltd.</institution>, <addr-line>Auckland</addr-line>, <country>New Zealand</country></aff>
      <aff id="aff8"><sup>8</sup><institution>Department of Neurosurgery, Auckland District Health Board</institution>, <addr-line>Auckland</addr-line>, <country>New Zealand</country></aff>
      <aff id="aff9"><sup>9</sup><institution>Department of Molecular Virology, Immunology and Medical Genetics, Neuroscience and Neurological Surgery, Ohio State University</institution>, <addr-line>Columbus, OH</addr-line>, <country>USA</country></aff>
      <aff id="aff10"><sup>10</sup><institution>Centre for Brain Research, University of Auckland</institution>, <addr-line>Auckland</addr-line>, <country>New Zealand</country></aff>
      <aff id="aff11"><sup>11</sup><institution>LabPlus Haematology, Auckland District Health Board</institution>, <addr-line>Auckland</addr-line>, <country>New Zealand</country></aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Sven Bilke, National Institutes of Health, USA</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Josh Waterfall, National Institutes of Health, USA; Anna DeFazio, University of Sydney at Westmead Millennium Institute, Australia</p>
        </fn>
        <corresp content-type="corresp" id="cor1">*Correspondence: Maggie L. Kalev-Zylinska, Department of Molecular Medicine and Pathology, University of Auckland, 85 Park Road, Grafton, Auckland, ACM 1142, New Zealand e-mail: <email>m.kalev@auckland.ac.nz</email></corresp>
        <fn fn-type="other" id="fn001">
          <p>This article was submitted to Cancer Genetics, a section of the journal Frontiers in Oncology.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <volume>3</volume>
      <elocation-id>333</elocation-id>
      <history>
        <date date-type="received">
          <day>02</day>
          <month>11</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright Â© 2014 Dâmello, Flanagan, Green, Leung, Askarian-Amiri, Joseph, McCrystal, Isaacs, Shaw, Furneaux, During, Finlay, Baguley and Kalev-Zylinska.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Previous whole-exome sequencing has demonstrated that melanoma tumors harbor mutations in the <italic>GRIN2A</italic> gene. <italic>GRIN2A</italic> encodes the regulatory GluN2A subunit of the glutamate-gated <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor (NMDAR), involvement of which in melanoma remains undefined. Here, we sequenced coding exons of <italic>GRIN2A</italic> in 19 low-passage melanoma cell lines derived from patients with metastatic melanoma. Potential mutation impact was evaluated <italic>in silico</italic>, including within the GluN2A crystal structure, and clinical correlations were sought. We found that of 19 metastatic melanoma tumors, four (21%) carried five missense mutations in the evolutionarily conserved domains of <italic>GRIN2A</italic>; two were previously reported. Melanoma cells that carried these mutations were treatment-naÃ¯ve. Sorting intolerant from tolerant analysis predicted that S349F, G762E, and P1132L would disrupt protein function. When modeled into the crystal structure of GluN2A, G762E was seen to potentially alter GluN1âGluN2A interactions and ligand binding, implying disruption to NMDAR functionality. Patients whose tumors carried non-synonymous <italic>GRIN2A</italic> mutations had faster disease progression and shorter overall survival (<italic>P</italic>â&lt;â0.05). This was in contrast to the <italic>BRAF</italic> V600E mutation, found in 58% of tumors but showing no correlation with clinical outcome (<italic>P</italic>â=â0.963). Although numbers of patients in this study are small, and firm conclusions about the association between <italic>GRIN2A</italic> mutations and poor clinical outcome cannot be drawn, our results highlight the high prevalence of <italic>GRIN2A</italic> mutations in metastatic melanoma and suggest for the first time that mutated NMDARs impact melanoma progression.</p>
      </abstract>
      <kwd-group>
        <kwd>melanoma</kwd>
        <kwd>
          <italic>GRIN2A</italic>
        </kwd>
        <kwd>mutation</kwd>
        <kwd>GluN2A</kwd>
        <kwd>NMDAR</kwd>
        <kwd>NMDA receptor</kwd>
        <kwd>glutamate</kwd>
        <kwd>prognosis</kwd>
      </kwd-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="5"/>
        <equation-count count="0"/>
        <ref-count count="29"/>
        <page-count count="9"/>
        <word-count count="5674"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="S1">
      <title>Introduction</title>
      <p>The genomic revolution of recent years has led to substantial advances in the cataloging of mutations in melanoma, most notable of which have been activating mutations in <italic>BRAF</italic>, <italic>NRAS</italic>, and <italic>KIT</italic> genes (<xref ref-type="bibr" rid="B1">1</xref>). The presence of these mutations helps to guide treatment with RAF, MEK, and KIT inhibitors, but they do not predict disease progression or survival of patients (<xref ref-type="bibr" rid="B2">2</xref>). In general, the usefulness of molecular biomarkers in determining prognosis in melanoma remains limited.</p>
      <p>Mutations in <italic>GRIN2A</italic> have been reported in up to a third of melanoma samples (<xref ref-type="bibr" rid="B3">3</xref>), although there is wide variation between studies (<xref ref-type="bibr" rid="B4">4</xref>â<xref ref-type="bibr" rid="B7">7</xref>) and no data on their clinical relevance. The <italic>GRIN2A</italic> gene, located on chromosome 16p13.2, encodes the GluN2A protein, a regulatory subunit of the glutamate-gated <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor (NMDAR) (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>). NMDARs are best known for their roles in the brain; hence, the finding of <italic>GRIN2A</italic> mutations in melanoma had been unexpected. Nevertheless, NMDARs have attracted attention for their potential contribution in cancer due to the effects on cell death, survival, and migration (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). Excessive NMDAR activation overloads the cell with calcium and leads to cell death (<xref ref-type="bibr" rid="B12">12</xref>). On the other hand, normal NMDAR activity promotes cell survival through the phosphatidylinositol 3-kinase (PI3-K) and extracellular signal-regulated kinase (ERK) signaling pathways (<xref ref-type="bibr" rid="B13">13</xref>). In addition, NMDAR effects on cell migration may affect tumor spread in tissue (<xref ref-type="bibr" rid="B10">10</xref>). Current knowledge on the NMDARs in the context of melanoma is limited, although expression of GluN2A in both normal and malignant melanocytes has been demonstrated (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). NMDAR inhibitors reduce migration and proliferation of melanoma cells <italic>in vitro</italic> (<xref ref-type="bibr" rid="B15">15</xref>).</p>
      <p>In response to the previously published exome sequencing data (<xref ref-type="bibr" rid="B3">3</xref>), we have investigated the prevalence of <italic>GRIN2A</italic> mutations in 19 low-passage metastatic melanoma cell lines out of over a 100 developed in our institution, and retrospectively correlated the presence of <italic>GRIN2A</italic> mutations with patient outcome.</p>
    </sec>
    <sec sec-type="materials|methods" id="S2">
      <title>Materials and Methods</title>
      <sec id="S2-1">
        <title>Patients and tumor material</title>
        <p>Low-passage melanoma cell lines derived from 19 patients with metastatic melanoma treated at two independent national sites were used in this study (Table <xref ref-type="supplementary-material" rid="SM2">S1</xref> in Supplementary Material). Written informed consent was obtained from all participants prior to enrolment; all study procedures were approved by Northern A Health and Disability Human Ethics Committee. This was not a clinical trial, and study procedures did not affect patient management in any way. Patients underwent skin, lymph node, or distant organ biopsies for diagnosis, staging, or treatment, as required clinically. Excess tissue was used to establish melanoma cell lines, as described (<xref ref-type="bibr" rid="B16">16</xref>). Cell lines for sequencing were chosen randomly out of over a 100 previously established in our center; all were passaged &lt;30 times. Cells were grown in 25 or 75âcm<sup>2</sup> flasks to 75% confluency in a low-oxygen humidified incubator (37Â°C, 5% O<sub>2</sub>, and 5% CO<sub>2</sub> in nitrogen). Cultures were maintained in Alpha-modified Minimal Essential Medium (Sigma-Aldrich, Saint Louis, MO, USA) containing 5% fetal bovine serum (Life Technologies, Carlsbad, CA, USA), penicillin (100âunitsâml<sup>â1</sup>), streptomycin (100âÎ¼gâml<sup>â1</sup>) (Sigma-Aldrich), insulin (5âÎ¼gâml<sup>â1</sup>), transferrin (5âÎ¼gâml<sup>â1</sup>), and sodium selenite (5ângâml<sup>â1</sup>) (Roche Applied Science, San Diego, CA, USA). Melanoma cells were sub-cultured weekly to maintain them in a proliferative state.</p>
        <p>Normal human epidermal melanocytes were used as control cells (HEMa-LP, Life Technologies); we did not have access to non-tumor tissue from patients. Melanocytes were cultured in Medium 254 (M-254-500; Life Technologies) supplemented with Human Melanocyte Growth Supplement (Life Technologies). Cultures were maintained in a humidified incubator (5% CO<sub>2</sub> in air) at 37Â°C. Melanocytes were sub-cultured every 4âweeks.</p>
      </sec>
      <sec id="S2-2">
        <title>Sequencing</title>
        <p>DNA was isolated using a PureLink Genomic DNA kit (Life Technologies), according to the manufacturerâs instructions. Concentrations and purity of DNA were determined using a nanodrop spectrophotometer (ND-1000, NanoDrop, ThermoFisher Scientific, Rockford, IL, USA). Twelve coding exons of <italic>GRIN2A</italic> (numbered 3â14), including their flanking intronic regions, were sequenced using Sanger method. The sequencing primers were as previously reported (<xref ref-type="bibr" rid="B3">3</xref>), except for 7Reverse (5â²-GCAGGCCCTTTGTCTGAGTA-3â²) and 8Forward (5â²-CCTTGCATCCAGGTGGTC-3â²), which we designed using Primer3web version 4.0.0 software<xref ref-type="fn" rid="fn1"><sup>1</sup></xref> to reduce interference from polyA sequences located in the intron between <italic>GRIN2A</italic> exons 7 and 8. PCR conditions for all primers are provided in Table <xref ref-type="table" rid="T1">1</xref>. PCR reactions were performed in a final volume of 25âÎ¼l 1Ã PCR buffer containing 50â100âng DNA, 0.3âÎ¼M forward and reverse primers each, 5âU Expand High Fidelity Enzyme mix (Roche Applied Science), 0.2âmM deoxynucleoside triphosphates, and 1.5âmM MgCl<sub>2</sub>. Bovine serum albumin (3âng Î¼l<sup>â1</sup>; Life Technologies) was used to counteract PCR inhibition where required. The correct sizes of the amplicons were confirmed on 2% agarose gels with DNA visualized with GelRed (Biotium, Hayward, CA, USA). DNA concentrations were estimated against Low-Mass Ladder (Life technologies). Sequencing was performed in two directions using ABI Prism 3730xl Genetic Analyzer with the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kit, version 3.1 (Applied Biosystems, Foster City, CA, USA).</p>
        <table-wrap id="T1" position="float">
          <label>Table 1</label>
          <caption>
            <p><bold>PCR cycling conditions used to amplify <italic>GRIN2A</italic> sequences</bold>.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Amplicon name</th>
                <th align="center" rowspan="1" colspan="1">Amplicon size (bp)</th>
                <th align="left" rowspan="1" colspan="1">Denaturation</th>
                <th align="left" rowspan="1" colspan="1">Annealing</th>
                <th align="left" rowspan="1" colspan="1">Extension</th>
                <th align="center" rowspan="1" colspan="1">Cycles number</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_1 and 2</td>
                <td align="center" rowspan="1" colspan="1">710</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">66Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 45âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_3 and 4</td>
                <td align="center" rowspan="1" colspan="1">763</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_5</td>
                <td align="center" rowspan="1" colspan="1">331</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_6</td>
                <td align="center" rowspan="1" colspan="1">464</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_7</td>
                <td align="center" rowspan="1" colspan="1">350</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_8</td>
                <td align="center" rowspan="1" colspan="1">295</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_9</td>
                <td align="center" rowspan="1" colspan="1">362</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">68Â°C, 30s</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1">35</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_10</td>
                <td align="center" rowspan="1" colspan="1">428</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1">for all</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_11</td>
                <td align="center" rowspan="1" colspan="1">372</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_12</td>
                <td align="center" rowspan="1" colspan="1">373</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_13</td>
                <td align="center" rowspan="1" colspan="1">381</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_14</td>
                <td align="center" rowspan="1" colspan="1">397</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 30âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_15 and 16</td>
                <td align="center" rowspan="1" colspan="1">633</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 45âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_17 and 18</td>
                <td align="center" rowspan="1" colspan="1">759</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 45âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"><italic>GRIN2A</italic>_19 and 20</td>
                <td align="center" rowspan="1" colspan="1">758</td>
                <td align="left" rowspan="1" colspan="1">94Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">60Â°C, 30âs</td>
                <td align="left" rowspan="1" colspan="1">72Â°C, 45âs</td>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The <italic>BRAF</italic> V600E mutation status had been determined previously for most cell lines (<xref ref-type="bibr" rid="B17">17</xref>). For the remaining samples, Cobas<sup>Â®</sup> 4800 <italic>BRAF</italic> Mutation Test (Roche Molecular Systems, Pleasanton, CA, USA) was used.</p>
      </sec>
      <sec id="S2-3">
        <title>Sequence analysis and prediction of mutation impact</title>
        <p>Exon sequences of <italic>GRIN2A</italic> were analyzed by reference to human <italic>GRIN2A</italic> (GenBank accession number NG_011812; RefSeqGene number GI: 226492187) using Geneious Pro 5.6.4 software (Biomatters, Auckland, New Zealand). To help predict if amino acid substitutions would affect protein function, Sorting Intolerant from Tolerant (SIFT) analysis of mutations was performed<xref ref-type="fn" rid="fn2"><sup>2</sup></xref> (<xref ref-type="bibr" rid="B18">18</xref>), applying UniProt SWISS-PROT 57.15 database. Catalog of somatic mutations in cancer (COSMIC)<xref ref-type="fn" rid="fn3"><sup>3</sup></xref> and MelanomaDB (<xref ref-type="bibr" rid="B19">19</xref>) databases were interrogated to search for <italic>GRIN2A</italic> mutations previously found in melanoma. Common germline single nucleotide polymorphisms (SNPs) in <italic>GRIN2A</italic> were eliminated using the NCBI database of SNPs<xref ref-type="fn" rid="fn4"><sup>4</sup></xref> (<xref ref-type="bibr" rid="B20">20</xref>).</p>
      </sec>
      <sec id="S2-4">
        <title>Modeling mutation impact</title>
        <p>The G762E mutation was modeled into the X-ray crystal structure of the GluN1âGluN2A S1S2 heterodimer using Modeller 9.1 (<xref ref-type="bibr" rid="B21">21</xref>) and the Protein Data Bank entry 2A5T (<xref ref-type="bibr" rid="B22">22</xref>) as the template. Ten models were constructed using two rounds of optimization with the slow autoschedule and molecular dynamics refinement options; all other settings were kept at default values. The models were superimposed on the 2A5T heterodimer using PyMol (<xref ref-type="bibr" rid="B23">23</xref>) and inspected visually.</p>
      </sec>
      <sec id="S2-5">
        <title>Collection of clinical data and statistical analysis</title>
        <p>Data on antecedent primary melanoma, disease progression, and treatment were obtained from a retrospective review of patient medical records. Melanoma staging was determined clinically based on the criteria designated by the American Joint Committee on Cancer (<xref ref-type="bibr" rid="B24">24</xref>). In this system, patients with lymph node metastases are designated as stage III; stage IV disease is defined by the presence of distant organ metastases. Overall survival is shown as the length of time from the initial diagnosis of melanoma to death. Considering that patient groups were small in this study, we presented quantitative data as median (range) (Table <xref ref-type="table" rid="T2">2</xref>) to best demonstrate sample distribution. To compare groups, cross-tabulations with significance tests were performed for data in categories. Analysis for mean differences between groups was performed using one-way ANOVA. Differences in time to event data were analyzed for the effect of <italic>GRIN2A</italic> mutation status using the survival analysis method (log-rank test). KaplanâMeier curves were generated to plot time to events (such as development of lymph node or distant organ metastases, or death) for individual patients (dot plots are provided as Supplemental Material). Statistical analysis was conducted using IBM SPSS Statistics software package for Windows, version 19.0 (Chicago, IL, USA) (<xref ref-type="bibr" rid="B25">25</xref>). <italic>P</italic> values &lt;0.05 were considered statistically significant.</p>
        <table-wrap id="T2" position="float">
          <label>Table 2</label>
          <caption>
            <p><bold>Clinical characteristics for all patients, according to the presence or absence of <italic>GRIN2A</italic> mutations in tumor-derived cell lines</bold>.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1"/>
                <th align="left" rowspan="1" colspan="1">All patients</th>
                <th align="left" rowspan="1" colspan="1">Non-synonymous <italic>GRIN2A</italic> mutations</th>
                <th align="left" rowspan="1" colspan="1">Synonymous <italic>GRIN2A</italic> mutations only</th>
                <th align="center" rowspan="1" colspan="1">Non-mutated <italic>GRIN2A</italic></th>
                <th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th>
              </tr>
              <tr>
                <th align="left" rowspan="1" colspan="1"/>
                <th align="left" rowspan="1" colspan="1"><italic>n</italic>â=â19</th>
                <th align="left" rowspan="1" colspan="1"><italic>n</italic>â=â4</th>
                <th align="left" rowspan="1" colspan="1"><italic>n</italic>â=â3</th>
                <th align="center" rowspan="1" colspan="1"><italic>n</italic>â=â12</th>
                <th align="left" rowspan="1" colspan="1"/>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Age: median (range) years</td>
                <td align="left" rowspan="1" colspan="1">54 (36â81)</td>
                <td align="left" rowspan="1" colspan="1">58 (36â69)</td>
                <td align="left" rowspan="1" colspan="1">46 (40â69)</td>
                <td align="left" rowspan="1" colspan="1">56 (38â81)</td>
                <td align="left" rowspan="1" colspan="1">0.916<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Males <italic>n</italic> (%)</td>
                <td align="left" rowspan="1" colspan="1">13 (68)</td>
                <td align="left" rowspan="1" colspan="1">4 (100)</td>
                <td align="left" rowspan="1" colspan="1">1 (33)</td>
                <td align="left" rowspan="1" colspan="1">8 (67)</td>
                <td align="left" rowspan="1" colspan="1">0.168<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Duration of known melanoma prior to enrolment: median (range) months</td>
                <td align="left" rowspan="1" colspan="1">31 (0â211)</td>
                <td align="left" rowspan="1" colspan="1">14 (0â30)</td>
                <td align="left" rowspan="1" colspan="1">6 (4â56)</td>
                <td align="left" rowspan="1" colspan="1">88 (1â211)</td>
                <td align="left" rowspan="1" colspan="1">0.110<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Patients with distant metastases at enrolment: <italic>n</italic> (%)<xref ref-type="table-fn" rid="tfn3"><sup>c</sup></xref></td>
                <td align="left" rowspan="1" colspan="1">12 (63)</td>
                <td align="left" rowspan="1" colspan="1">1 (25)</td>
                <td align="left" rowspan="1" colspan="1">2 (67)</td>
                <td align="left" rowspan="1" colspan="1">9 (75)</td>
                <td align="left" rowspan="1" colspan="1">0.198<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Patients treated with chemotherapy: <italic>n</italic> (%)</td>
                <td align="left" rowspan="1" colspan="1">5 (26)</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">2 (67)</td>
                <td align="left" rowspan="1" colspan="1">3 (25)</td>
                <td align="left" rowspan="1" colspan="1">0.149<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Patients treated with autologous tumor vaccine: <italic>n</italic> (%)</td>
                <td align="left" rowspan="1" colspan="1">3 (16)</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">1 (33)<xref ref-type="table-fn" rid="tfn4"><sup>d</sup></xref></td>
                <td align="left" rowspan="1" colspan="1">2 (17)</td>
                <td align="left" rowspan="1" colspan="1">0.492<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Progression from diagnosis to lymph node metastases (stage III): median (range) months</td>
                <td align="left" rowspan="1" colspan="1">9 (0â140)</td>
                <td align="left" rowspan="1" colspan="1">0 (0â27)</td>
                <td align="left" rowspan="1" colspan="1">6 (0â17)</td>
                <td align="left" rowspan="1" colspan="1">37 (0â140)</td>
                <td align="left" rowspan="1" colspan="1">0.040<xref ref-type="table-fn" rid="tfn5"><sup>e</sup></xref></td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Progression from diagnosis to distant organ metastases (stage IV): median (range) months</td>
                <td align="left" rowspan="1" colspan="1">34 (0â205)</td>
                <td align="left" rowspan="1" colspan="1">2 (0â34)</td>
                <td align="left" rowspan="1" colspan="1">14 (4â35)</td>
                <td align="left" rowspan="1" colspan="1">108 (1â205)</td>
                <td align="left" rowspan="1" colspan="1">0.012<xref ref-type="table-fn" rid="tfn5"><sup>e</sup></xref></td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Progression from diagnosis to death (i.e. overall survival): median (range) months</td>
                <td align="left" rowspan="1" colspan="1">36 (4â229)</td>
                <td align="left" rowspan="1" colspan="1">5 (4â36)</td>
                <td align="left" rowspan="1" colspan="1">15 (5â61)</td>
                <td align="left" rowspan="1" colspan="1">114 (4â229)</td>
                <td align="left" rowspan="1" colspan="1">0.013<xref ref-type="table-fn" rid="tfn5"><sup>e</sup></xref></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><italic>âAll patientsâ column demonstrates patient characteristics at enrolment into the study. The <italic>P</italic> values are for the effect of <italic>GRIN2A</italic> mutation status, so the data in the last three columns were used for statistical analysis (i.e. excluding the âAll patientsâ column)</italic>.</p>
            <fn id="tfn1">
              <p><sup>a</sup> One-way ANOVA</p>
            </fn>
            <fn id="tfn2">
              <p><sup>b</sup> Ï<sup>2</sup> test</p>
            </fn>
            <fn id="tfn3">
              <p><italic><sup>c</sup> Other patients had lymph node metastases at enrolment</italic>.</p>
            </fn>
            <fn id="tfn4">
              <p><italic><sup>d</sup> This patient also received chemotherapy</italic>.</p>
            </fn>
            <fn id="tfn5">
              <p><italic><sup>e</sup> Log-rank <italic>P</italic> values reflect differences between patients with non-mutated <italic>GRIN2A</italic> versus patients with non-synonymous <italic>GRIN2A</italic> mutations. When patients with synonymous <italic>GRIN2A</italic> mutations were compared, differences were not statistically significant (pairwise <italic>P</italic> values are shown in Figures <xref ref-type="fig" rid="F3">3</xref> and <xref ref-type="fig" rid="F4">4</xref> and Figure <xref ref-type="supplementary-material" rid="SM1">S1</xref> in Supplementary Material)</italic>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
    </sec>
    <sec id="S3">
      <title>Results</title>
      <p>Nineteen low-passage melanoma cell lines, derived from 19 patients with metastatic melanoma, were used in this study to sequence coding exons of <italic>GRIN2A</italic>, together with their flanking intronic regions. Patient characteristics at enrolment into the study are shown in Table <xref ref-type="table" rid="T2">2</xref> (âAll patientsâ column). Apart from two patients who presented with either bulky or disseminated disease and entered this study on presentation, other patients had a prior history of skin melanoma dating back a median of 34 (1â211) months. Seventeen patients had primary skin lesions in sun-exposed areas; in the other two, primary skin lesions remained occult. At the time of enrolment (between 1989 and 2010), 12 patients (63%) had metastatic melanoma in distant organs (stage IV disease) and 7 patients (37%) had lymph node involvement (stage III disease). All patients were managed surgically and with regional radiotherapy. Five patients also received chemotherapy â three had POC (procarbazine, vincristine, and lomustine), one temozolomide, and one DTIC (dacarbazine) â with the number of chemotherapy cycles ranging from one to six. Autologous tumor vaccine was used in three patients (in one, after an unsuccessful course of chemotherapy). One patient also received an experimental vascular disrupting agent within a phase I clinical trial, as well as interferon Î±. No patient received BRAF inhibitors. Treatment was the decision of a clinical team, independent of research procedures. One patient remained free of melanoma 12âyears after nodal recurrence. The other 18 patients have all died of their disease. The median survival time was 36 (4â229) months.</p>
      <sec id="S3-6">
        <title><italic>GRIN2A</italic> mutations and predicted impact on protein structure</title>
        <p>Sequencing of <italic>GRIN2A</italic> was conducted using cell lines derived from tumors spread to lymph nodes in 12 patients (63%), distant organs (brain, small bowel, ascites, or lung) (five patients; 26%), or locoregional metastases (two patients; 11%). All cell lines used in this study were passaged &lt;30 times, and were generated from treatment-naÃ¯ve tumors, except for NZM 017 and NZM 040, which were derived from patients who received prior immunotherapy or chemotherapy, respectively (Table <xref ref-type="supplementary-material" rid="SM2">S1</xref> in Supplementary Material).</p>
        <p>Of 19 tumor samples tested, four (21%) carried five non-synonymous mutations in <italic>GRIN2A</italic> (Figure <xref ref-type="fig" rid="F1">1</xref>; Table <xref ref-type="table" rid="T3">3</xref>). Tumors that carried these mutations were treatment-naÃ¯ve, excluding therapy effect. All non-synonymous mutations were missense: three clustered in exon 14 (G889E, P1132L, P1133S), and the other two in exon 5 (S349F) and exon 12 (G762E) (Figure <xref ref-type="fig" rid="F1">1</xref>). These locations corresponded with the evolutionarily conserved domains in the GluN2A protein: C-terminal, N-terminal, and the S2 segment, respectively (Figure <xref ref-type="fig" rid="F1">1</xref>). The S2 segment forms the ligand binding domain, and the intracytoplasmic C-terminus is involved in intracellular signaling and interactions with the cytoskeleton. Two mutations, G889E and P1132L, were previously reported [Ref. (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B17">17</xref>), respectively]. SIFT analysis predicted that S349F, G762E, and P1133S would deleteriously affect protein function (Table <xref ref-type="table" rid="T3">3</xref>).</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p><bold><italic>GRIN2A</italic> mutations in melanoma cell lines</bold>. <bold>(A)</bold> Schematic of the GluN2A protein together with the non-synonymous (in red) and synonymous (in gray) mutations in <italic>GRIN2A</italic>. <italic>GRIN2A</italic> cDNA is 4392 nucleotides long and can be divided into sections encoding evolutionarily conserved domains in the GluN2A protein. The first and last amino acid residues of the SP, S1, S2, and M1âM4 domains are numbered. Symbols â´ and â¾ mark mutations that coincided in the same tumor samples; *marks mutations reported previously. Abbreviations: SP, signal peptide; NTD, N-terminal domain; S1 and S2 segments form the glutamate-binding domain; M1âM4 transmembrane segments form the ion channel pore; CTD, C-terminal domain. <bold>(B)</bold> Sanger sequencing output of non-synonymous mutations in <italic>GRIN2A</italic>. Each panel represents a non-synonymous mutation detected. Nucleotides are labeled below their respective peaks. Corresponding amino acid sequences are indicated.</p>
          </caption>
          <graphic xlink:href="fonc-03-00333-g001"/>
        </fig>
        <table-wrap id="T3" position="float">
          <label>Table 3</label>
          <caption>
            <p><bold>Non-synonymous mutations in <italic>GRIN2A</italic></bold>.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">NZM cell line</th>
                <th align="left" rowspan="1" colspan="1">Substitution and nucleotide number</th>
                <th align="left" rowspan="1" colspan="1">Amino acid change</th>
                <th align="left" rowspan="1" colspan="1">Exon</th>
                <th align="left" rowspan="1" colspan="1">Zygosity</th>
                <th align="left" rowspan="1" colspan="1">SIFT score</th>
                <th align="left" rowspan="1" colspan="1">SIFT median</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">061</td>
                <td align="left" rowspan="1" colspan="1">Câ&gt;âT</td>
                <td align="left" rowspan="1" colspan="1">S349F</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">3.33</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.1046</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.291693</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">061</td>
                <td align="left" rowspan="1" colspan="1">Gâ&gt;âA</td>
                <td align="left" rowspan="1" colspan="1">G762E</td>
                <td align="left" rowspan="1" colspan="1">12</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">3.08</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.2285</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.384407</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">007</td>
                <td align="left" rowspan="1" colspan="1">Gâ&gt;âA</td>
                <td align="left" rowspan="1" colspan="1">G889E</td>
                <td align="left" rowspan="1" colspan="1">14</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
                <td align="left" rowspan="1" colspan="1">0.29</td>
                <td align="left" rowspan="1" colspan="1">3.24</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.2666</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.417877</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">100</td>
                <td align="left" rowspan="1" colspan="1">Câ&gt;âT</td>
                <td align="left" rowspan="1" colspan="1">P1132L</td>
                <td align="left" rowspan="1" colspan="1">14</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
                <td align="left" rowspan="1" colspan="1">0.2</td>
                <td align="left" rowspan="1" colspan="1">3.32</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.3395</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.418606</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">003</td>
                <td align="left" rowspan="1" colspan="1">Câ&gt;âT</td>
                <td align="left" rowspan="1" colspan="1">P1133S</td>
                <td align="left" rowspan="1" colspan="1">14</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">3.32</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.3397</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.418608</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><italic>Mutations are listed in the order of location along the sequence. Deleterious substitutions were predicted from SIFT scores â¤0.05</italic>.</p>
            <p><italic>c, cDNA; g, genomic DNA; hetero-, heterozygous; SIFT, sorting intolerant from tolerant analysis</italic>.</p>
          </table-wrap-foot>
        </table-wrap>
        <p>Five synonymous mutations were also detected (Table <xref ref-type="table" rid="T4">4</xref>), as well as four SNPs (Table <xref ref-type="table" rid="T5">5</xref>); SNPs were excluded from further analysis. F186F synonymous mutation was found in the NZM 040 cell line derived from patient who received two cycles of POC chemotherapy 8âmonths prior to cell line derivation (Table <xref ref-type="supplementary-material" rid="SM2">S1</xref> in Supplementary Material). In this instance, the possibility that therapy contributed to the presence of this mutation could not be ruled out.</p>
        <table-wrap id="T4" position="float">
          <label>Table 4</label>
          <caption>
            <p><bold>Synonymous mutations in <italic>GRIN2A</italic></bold>.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">NZM cell line</th>
                <th align="left" rowspan="1" colspan="1">Substitution and nucleotide number</th>
                <th align="left" rowspan="1" colspan="1">Amino acid</th>
                <th align="left" rowspan="1" colspan="1">Exon</th>
                <th align="left" rowspan="1" colspan="1">Zygosity</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">061</td>
                <td align="left" rowspan="1" colspan="1">Câ&gt;âT</td>
                <td align="left" rowspan="1" colspan="1">F177F</td>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.531</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.244320</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">040</td>
                <td align="left" rowspan="1" colspan="1">Câ&gt;âT</td>
                <td align="left" rowspan="1" colspan="1">F186F</td>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.558</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.244347</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">055</td>
                <td align="left" rowspan="1" colspan="1">Câ&gt;âT</td>
                <td align="left" rowspan="1" colspan="1">L794L</td>
                <td align="left" rowspan="1" colspan="1">13</td>
                <td align="left" rowspan="1" colspan="1">Homo-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.2380</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.413689</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">003</td>
                <td align="left" rowspan="1" colspan="1">Câ&gt;âT</td>
                <td align="left" rowspan="1" colspan="1">F1344F</td>
                <td align="left" rowspan="1" colspan="1">14</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.4032</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.419243</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">086</td>
                <td align="left" rowspan="1" colspan="1">Aâ&gt;âC</td>
                <td align="left" rowspan="1" colspan="1">A1409A</td>
                <td align="left" rowspan="1" colspan="1">14</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.4227</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.419438</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><italic>Mutations are listed in the order of location along the sequence</italic>.</p>
            <p><italic>c, cDNA; g, genomic DNA; hetero-, heterozygous; homo-, homozygous</italic>.</p>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="T5" position="float">
          <label>Table 5</label>
          <caption>
            <p><bold><italic>GRIN2A</italic> SNPs in tumor-derived cell lines</bold>.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">NZM cell line</th>
                <th align="left" rowspan="1" colspan="1">Substitution and nucleotide number</th>
                <th align="left" rowspan="1" colspan="1">Amino acid</th>
                <th align="left" rowspan="1" colspan="1">Exon</th>
                <th align="left" rowspan="1" colspan="1">Zygosity</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">011</td>
                <td align="left" rowspan="1" colspan="1">Gâ&gt;âA</td>
                <td align="left" rowspan="1" colspan="1">L425L</td>
                <td align="left" rowspan="1" colspan="1">6</td>
                <td align="left" rowspan="1" colspan="1">Homo-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">007</td>
                <td align="left" rowspan="1" colspan="1">c.1275</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">055</td>
                <td align="left" rowspan="1" colspan="1">g.332946</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">001</td>
                <td align="left" rowspan="1" colspan="1">Gâ&gt;âA</td>
                <td align="left" rowspan="1" colspan="1">L425L</td>
                <td align="left" rowspan="1" colspan="1">6</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">034</td>
                <td align="left" rowspan="1" colspan="1">c.1275</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">061</td>
                <td align="left" rowspan="1" colspan="1">g.332946</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">011</td>
                <td align="left" rowspan="1" colspan="1">Gâ&gt;âC</td>
                <td align="left" rowspan="1" colspan="1">R695R</td>
                <td align="left" rowspan="1" colspan="1">11</td>
                <td align="left" rowspan="1" colspan="1">Homo-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">007</td>
                <td align="left" rowspan="1" colspan="1">c.2085</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">055</td>
                <td align="left" rowspan="1" colspan="1">g.360408</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">01</td>
                <td align="left" rowspan="1" colspan="1">Gâ&gt;âC</td>
                <td align="left" rowspan="1" colspan="1">R695R</td>
                <td align="left" rowspan="1" colspan="1">11</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">061</td>
                <td align="left" rowspan="1" colspan="1">c.2085</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.360408</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">006</td>
                <td align="left" rowspan="1" colspan="1">Câ&gt;âT</td>
                <td align="left" rowspan="1" colspan="1">W730W</td>
                <td align="left" rowspan="1" colspan="1">12</td>
                <td align="left" rowspan="1" colspan="1">Homo-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.2190</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.384312</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">003</td>
                <td align="left" rowspan="1" colspan="1">Câ&gt;âA</td>
                <td align="left" rowspan="1" colspan="1">N1076K</td>
                <td align="left" rowspan="1" colspan="1">14</td>
                <td align="left" rowspan="1" colspan="1">Hetero-</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">c.3228</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1">g.418439</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><italic>c, cDNA; g, genomic DNA; homo-, homozygous; hetero-, heterozygous</italic>.</p>
          </table-wrap-foot>
        </table-wrap>
        <p>We modeled the G762E missense substitution into the 3-dimensional X-ray crystal structure of the GluN1âGluN2A heterodimer, 2A5T (<xref ref-type="bibr" rid="B22">22</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>). This revealed that G762E was located in the distal âhingeâ of the glutamate-binding clam-shell-like region of GluN2A. In this location, the mutated glutamate residue was seen to interact with K531 in the GluN1 protein interfacing GluN2A in this region. While K531 formed a hydrogen bond with the backbone carbonyl of F524 in GluN2A, its proximity to the mutated glutamate side-chain (G762E) indicated the potential for new electrostatic interactions between G762E (in GluN2A) and K531 (in GluN1) (Figure <xref ref-type="fig" rid="F2">2</xref>) with the ability to alter interactions between GluN2A and GluN1 subunits and consequently, impact NMDAR functionality. Conformational changes that developed to accommodate G762E could also affect ligand binding, as the residue preceding G762E (Y761) was part of the glutamate-binding site (Figure <xref ref-type="fig" rid="F2">2</xref>) (<xref ref-type="bibr" rid="B26">26</xref>).</p>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p><bold>Model of G762E within the GluN1âGluN2A X-ray crystal structure</bold>. The S1S2 loop of GluN2A (in green) is shown interfacing with GluN1 (in cyan). A portion of the GluN2A agonist-binding site is on the left together with bound glutamate (Glut). G762E and F524 residues of GluN2A are 2.7 and 3.9âÃ away from K531 in GluN1, respectively; potential new electrostatic interactions are indicated as dashed lines. Nitrogen atoms are in blue, and oxygen in red.</p>
          </caption>
          <graphic xlink:href="fonc-03-00333-g002"/>
        </fig>
      </sec>
      <sec id="S3-7">
        <title>Clinical associations of <italic>GRIN2A</italic> mutations</title>
        <p>There was no difference in age and gender between patients whose melanoma lines carried <italic>GRIN2A</italic> mutations and those who did not (Table <xref ref-type="table" rid="T2">2</xref>). Two patients in this study presented with disseminated melanoma and both were found to carry non-synonymous mutations in <italic>GRIN2A</italic>. The other two patients with the non-synonymous <italic>GRIN2A</italic> mutations presented with skin lesions that spread to lymph nodes within 9 and 27âmonths, compared with a median of 37 (0â140) months for patients with non-mutated <italic>GRIN2A</italic> (<italic>P</italic>â=â0.041; Table <xref ref-type="table" rid="T2">2</xref>). Overall, patients with non-synonymous <italic>GRIN2A</italic> mutations had faster progression of melanoma from skin lesions to the involvement of lymph nodes (<italic>P</italic>â=â0.04) or distant organs (<italic>P</italic>â=â0.012), and shorter overall survival (<italic>P</italic>â=â0.013) compared with patients with non-mutated <italic>GRIN2A</italic> (Table <xref ref-type="table" rid="T2">2</xref>; Figures <xref ref-type="fig" rid="F3">3</xref> and <xref ref-type="fig" rid="F4">4</xref>A). The <italic>BRAF</italic> V600E mutation was found in 11 of 19 (58%) tumor samples but in contrast to <italic>GRIN2A</italic>, its presence showed no correlation with overall survival (<italic>P</italic>â=â0.963; Figure <xref ref-type="fig" rid="F4">4</xref>B; Table <xref ref-type="supplementary-material" rid="SM2">S1</xref> in Supplementary Material).</p>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <p><bold>Times of disease progression from diagnosis to lymph node (A) or distant organ (B) metastases for individual patients according to the presence or absence of <italic>GRIN2A</italic> mutations</bold>. Levels of statistical significance are shown. *Progression data for one patient with non-mutated <italic>GRIN2A</italic> was not available.</p>
          </caption>
          <graphic xlink:href="fonc-03-00333-g003"/>
        </fig>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p><bold>Overall survival according to the <italic>GRIN2A</italic> (A) or <italic>BRAF</italic> V600E (B) mutation status</bold>. Levels of statistical significance are shown. *Data for one patient with non-mutated <italic>GRIN2A</italic> (V600E absent) was not available.</p>
          </caption>
          <graphic xlink:href="fonc-03-00333-g004"/>
        </fig>
        <p>Seven patients in this study received systemic therapy â five had chemotherapy and another two autologous tumor vaccine (Table <xref ref-type="table" rid="T2">2</xref>). These were in addition to surgery and involved field radiotherapy used in all patients. When compared with patients managed with surgery and radiotherapy alone, the administration of systemic therapy did not change disease spread to lymph nodes (<italic>P</italic>â=â0.849), distant organs (<italic>P</italic>â=â0.499), or overall survival (<italic>P</italic>â=â0.843).</p>
        <p>Patients with isolated synonymous <italic>GRIN2A</italic> mutations (<italic>n</italic>â=â3) displayed a trend for poorer outcome, compared with patients with non-mutated <italic>GRIN2A</italic>, but this was not statistically significant (Figures <xref ref-type="fig" rid="F3">3</xref> and <xref ref-type="fig" rid="F4">4</xref>).</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="S4">
      <title>Discussion</title>
      <p>This study has shown that cell lines derived from 4 of 19 (21%) patients with metastatic melanoma carried five missense mutations in <italic>GRIN2A</italic>. They occurred in three of the four evolutionarily conserved domains of the GluN2A subunit of the NMDAR: the N-terminal, glutamate-binding, and C-terminal domains. All missense mutations were found in treatment-naÃ¯ve samples. The S349F, G762E, and P1132L substitutions were predicted by SIFT to disrupt protein function. When modeled into the crystal structure of GluN2A, the G762E substitution was seen to potentially alter GluN1âGluN2A interactions and ligand binding, implying disruption to the NMDAR functionality. Patients whose tumors carried non-synonymous mutations in <italic>GRIN2A</italic> had faster disease progression and shorter overall survival. Our findings suggest for the first time, to our knowledge, that <italic>GRIN2A</italic> mutations may drive melanoma progression.</p>
      <p>Our results are in agreement with the seminal whole-exome sequencing work, where non-synonymous mutations in <italic>GRIN2A</italic> were found in 26% of melanoma samples (<xref ref-type="bibr" rid="B3">3</xref>). Other exome-wide sequencing projects detected <italic>GRIN2A</italic> mutations at lower frequencies (<xref ref-type="bibr" rid="B4">4</xref>â<xref ref-type="bibr" rid="B7">7</xref>). The true frequency of <italic>GRIN2A</italic> mutations in melanoma remains uncertain, but our results support the high prevalence of <italic>GRIN2A</italic> mutations in metastatic melanoma (<xref ref-type="bibr" rid="B3">3</xref>). Possible causes for differences between studies include the stage of tumors tested, or biological heterogeneity of tumors influenced by demographic, geographical, or environmental factors. Our study demonstrates for the first time that patients with <italic>GRIN2A</italic> mutations may have more aggressive disease. Considering that there is currently no reliable genetic biomarker that predicts melanoma progression, <italic>GRIN2A</italic> mutation testing may offer valuable prognostic information. Earlier detection of highly aggressive tumors could assist faster introduction of new therapies for melanoma patients. We propose that the <italic>GRIN2A</italic> mutation testing be incorporated in larger prospective studies for further evaluation of our findings.</p>
      <p>Our work has obvious limitations. Patient numbers are small, and the clinical outcome was assessed retrospectively. We did not have access to non-diseased patient DNA to exclude germline polymorphisms (SNPs were excluded using online databases). Original tumor tissue is no longer available to confirm that these contained <italic>GRIN2A</italic> mutations found in cell lines, but an error in cell line authentication is extremely unlikely. Short tandem repeat profiling has been conducted on NZM cell lines to ensure authentication is possible in the future; however, profiles of original tumors are not available. Small sample size limits our conclusions, and confounders cannot be excluded. Nevertheless, the <italic>BRAF</italic> mutation status and systemic therapy had no effect on clinical outcome in these patients. Other possible limitations include the relatively late stage of patients at presentation and the selection of cell lines tested. Our success rate of establishing melanoma cell lines is at least 90%, but the possibility of bias toward melanomas that can be grown in culture cannot be ruled out.</p>
      <p>Synonymous mutations in <italic>GRIN2A</italic> associated with poorer patient outcome; however, these observations were not statistically significant. Recent studies indicate that synonymous mutations may be important in cancer, primarily through mechanisms that affect RNA processing and protein translation (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>). Further work in this area will be required to clarify if synonymous <italic>GRIN2A</italic> mutations play a role in melanoma biology.</p>
      <p>Our results have strong implications for basic research. The roles of NMDAR-mediated pathways in melanoma are still unknown and will require elucidation. Well-characterized melanoma cell lines with known mutations, such as those described in this manuscript, will be valuable tools to examine the mechanisms of action and consequences of specific <italic>GRIN2A</italic> mutations in melanoma tumors. We hypothesize that possible mechanisms through which G762E and other <italic>GRIN2A</italic> mutations interfere with the NMDAR include reduced NMDAR channel function and disturbed intracellular signaling downstream. Such effects would be most relevant under conditions of NMDAR overactivation, where excessive calcium uptake induces cell toxicity. The lack of NMDAR-mediated cell death could facilitate tumor progression. Our hypothesis is consistent with the previously suggested role for the NMDAR as a tumor suppressor (<xref ref-type="bibr" rid="B29">29</xref>). Other GluN subunits (if expressed in melanoma cells) could compensate for the GluN2A disruption or contribute additional functionality. NMDAR-mediated pro-cell-survival signaling could also provide oncogenic effects, in keeping with the functional dichotomy of the NMDAR (<xref ref-type="bibr" rid="B11">11</xref>).</p>
      <p>In conclusion, our study suggests that non-synonymous mutations in <italic>GRIN2A</italic> are present in approximately 20% of patients with metastatic melanoma and associate with faster disease progression and shorter overall survival. The most direct clinical implication of our work is that <italic>GRIN2A</italic> mutation status may allow earlier detection and hence faster treatments of patients with aggressive tumors. Our data also imply that NMDAR may be a novel molecular modifier in melanoma; hence, further studies into its biological role should be pursued.</p>
    </sec>
    <sec id="S5">
      <title>Author Contributions</title>
      <p>Stacey Ann N. Dâmello conducted experimental work, analyzed data, and wrote the manuscript together with Maggie L. Kalev-Zylinska; Jack U. Flanagan supervised structural modeling of mutation impact; Taryn N. Green, Euphemia Y. Leung, Marjan E. Askarian-Amiri, and Wayne R. Joseph provided advice and assisted experimental procedures; Michael R. McCrystal provided clinical advice; Richard J. Isaacs, James H. F. Shaw, and Christopher E. Furneaux contributed patient samples; Matthew J. During provided mentorship and advice; Graeme J. Finlay provided supervision and edited the manuscript; Bruce C. Baguley helped to design the study, provided supervision, and advice; Maggie L. Kalev-Zylinska designed the study, obtained and analyzed clinical data, provided supervision, and wrote the manuscript together with Stacey Ann N. Dâmello.</p>
    </sec>
    <sec id="S6">
      <title>Conflict of Interest Statement</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
    <sec sec-type="supplementary-material" id="S7">
      <title>Supplementary Material</title>
      <p>The Supplementary Material for this article can be found online at <uri xlink:type="simple" xlink:href="http://www.frontiersin.org/Journal/10.3389/fonc.2013.00333/abstract">http://www.frontiersin.org/Journal/10.3389/fonc.2013.00333/abstract</uri></p>
      <supplementary-material content-type="local-data" id="SM1">
        <label>Figure S1</label>
        <caption>
          <p><bold>Summary of disease progression events for patients with no, synonymous, and non-synonymous mutations in GRIN2A</bold>. Data points for individual patients are shown; horizontal lines mark median values in each group. Levels of statistical difference between groups are shown. *Disease progression data for one patient with non-mutated GRIN2A were not available.</p>
        </caption>
        <media xlink:href="74132_Kalev-Zylinska_Presentation1.PDF">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SM2">
        <label>Table S1</label>
        <caption>
          <p><bold>Summary of NZM cell lines tested in this study, together with their mutation status and systemic therapy received by patients prior to cell line establishment</bold>.</p>
        </caption>
        <media xlink:href="74132_Kalev-Zylinska_Presentation1.PDF">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>Sequencing was performed by Genetic Analysis Services at the University of Otago. Dr. Donald R. Love facilitated additional <italic>BRAF</italic> mutation testing at LabPlus, Auckland District Health Board. Alexander Trevarton advised on bioinformatics approaches and Nicholas Knowlton on statistical analysis. Funding: This study was supported by Auckland Medical Research Foundation (UOA3700909); Cancer Society (UOA3702269) and Glenn Family Foundation.</p>
    </ack>
    <fn-group>
      <fn id="fn1">
        <p>
          <sup>1</sup>
          <uri xlink:type="simple" xlink:href="http://primer3.wi.mit.edu/">http://primer3.wi.mit.edu/</uri>
        </p>
      </fn>
      <fn id="fn2">
        <p>
          <sup>2</sup>
          <uri xlink:type="simple" xlink:href="http://sift.jcvi.org/">http://sift.jcvi.org/</uri>
        </p>
      </fn>
      <fn id="fn3">
        <p>
          <sup>3</sup>
          <uri xlink:type="simple" xlink:href="http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/">http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/</uri>
        </p>
      </fn>
      <fn id="fn4">
        <p>
          <sup>4</sup>
          <uri xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP">http://www.ncbi.nlm.nih.gov/projects/SNP</uri>
        </p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Watson</surname><given-names>IR</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Arold</surname><given-names>ST</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Theurillat</surname><given-names>JP</given-names></name><etal/></person-group>
<article-title>A landscape of driver mutations in melanoma</article-title>. <source>Cell</source> (<year>2012</year>) <volume>150</volume>:<fpage>251</fpage>â<lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.06.024</pub-id><?supplied-pmid 22817889?><pub-id pub-id-type="pmid">22817889</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>S</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name></person-group>
<article-title>Which drug, and when, for patients with BRAF- mutant melanoma?</article-title>
<source>Lancet Oncol</source> (<year>2013</year>) <volume>14</volume>:<fpage>e60</fpage>â<lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70539-9</pub-id><?supplied-pmid 23369684?><pub-id pub-id-type="pmid">23369684</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Walia</surname><given-names>V</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Teer</surname><given-names>JK</given-names></name><name><surname>Prickett</surname><given-names>TD</given-names></name><name><surname>Gartner</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Exome sequencing identifies GRIN2A as frequently mutated in melanoma</article-title>. <source>Nat Genet</source> (<year>2011</year>) <volume>43</volume>:<fpage>442</fpage>â<lpage>6</lpage><pub-id pub-id-type="doi">10.1038/ng.810</pub-id><?supplied-pmid 21499247?><pub-id pub-id-type="pmid">21499247</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Deribe</surname><given-names>YL</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Protopopov</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Melanoma genome sequencing reveals frequent PREX2 mutations</article-title>. <source>Nature</source> (<year>2012</year>) <volume>485</volume>:<fpage>502</fpage>â<lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature11071</pub-id><?supplied-pmid 22622578?><pub-id pub-id-type="pmid">22622578</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krauthammer</surname><given-names>M</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Ha</surname><given-names>BH</given-names></name><name><surname>Evans</surname><given-names>P</given-names></name><name><surname>Bacchiocchi</surname><given-names>A</given-names></name><name><surname>McCusker</surname><given-names>JP</given-names></name><etal/></person-group>
<article-title>Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma</article-title>. <source>Nat Genet</source> (<year>2012</year>) <volume>44</volume>:<fpage>1006</fpage>â<lpage>14</lpage><pub-id pub-id-type="doi">10.1038/ng.2359</pub-id><?supplied-pmid 22842228?><pub-id pub-id-type="pmid">22842228</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolaev</surname><given-names>SI</given-names></name><name><surname>Rimoldi</surname><given-names>D</given-names></name><name><surname>Iseli</surname><given-names>C</given-names></name><name><surname>Valsesia</surname><given-names>A</given-names></name><name><surname>Robyr</surname><given-names>D</given-names></name><name><surname>Gehrig</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma</article-title>. <source>Nat Genet</source> (<year>2012</year>) <volume>44</volume>:<fpage>133</fpage>â<lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ng.1026</pub-id><?supplied-pmid 22197931?><pub-id pub-id-type="pmid">22197931</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>MS</given-names></name><name><surname>Woods</surname><given-names>SL</given-names></name><name><surname>Gartside</surname><given-names>MG</given-names></name><name><surname>Bonazzi</surname><given-names>VF</given-names></name><name><surname>Dutton-Regester</surname><given-names>K</given-names></name><name><surname>Aoude</surname><given-names>LG</given-names></name><etal/></person-group>
<article-title>Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing</article-title>. <source>Nat Genet</source> (<year>2012</year>) <volume>44</volume>:<fpage>165</fpage>â<lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ng.1041</pub-id><?supplied-pmid 22197930?><pub-id pub-id-type="pmid">22197930</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collingridge</surname><given-names>GL</given-names></name><name><surname>Olsen</surname><given-names>RW</given-names></name><name><surname>Peters</surname><given-names>J</given-names></name><name><surname>Spedding</surname><given-names>M</given-names></name></person-group>
<article-title>A nomenclature for ligand-gated ion channels</article-title>. <source>Neuropharmacology</source> (<year>2009</year>) <volume>56</volume>:<fpage>2</fpage>â<lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.06.063</pub-id><pub-id pub-id-type="pmid">18655795</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traynelis</surname><given-names>SF</given-names></name><name><surname>Wollmuth</surname><given-names>LP</given-names></name><name><surname>McBain</surname><given-names>CJ</given-names></name><name><surname>Menniti</surname><given-names>FS</given-names></name><name><surname>Vance</surname><given-names>KM</given-names></name><name><surname>Ogden</surname><given-names>KK</given-names></name><etal/></person-group>
<article-title>Glutamate receptor ion channels: structure, regulation, and function</article-title>. <source>Pharmacol Rev</source> (<year>2010</year>) <volume>62</volume>:<fpage>405</fpage>â<lpage>96</lpage><pub-id pub-id-type="doi">10.1124/pr.109.002451</pub-id><?supplied-pmid 20716669?><pub-id pub-id-type="pmid">20716669</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group>
<article-title>Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion</article-title>. <source>Cell</source> (<year>2013</year>) <volume>153</volume>:<fpage>86</fpage>â<lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.02.051</pub-id><?supplied-pmid 23540692?><pub-id pub-id-type="pmid">23540692</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>North</surname><given-names>WG</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Memoli</surname><given-names>VA</given-names></name><name><surname>Pang</surname><given-names>RH</given-names></name><name><surname>Lynch</surname><given-names>L</given-names></name></person-group>
<article-title>Breast cancer expresses functional NMDA receptors</article-title>. <source>Breast Cancer Res Treat</source> (<year>2010</year>) <volume>122</volume>:<fpage>307</fpage>â<lpage>14</lpage><pub-id pub-id-type="doi">10.1007/s10549-009-0556-1</pub-id><?supplied-pmid 19784770?><pub-id pub-id-type="pmid">19784770</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>A</given-names></name><name><surname>Tymianski</surname><given-names>M</given-names></name></person-group>
<article-title>Glutamate receptors, neurotoxicity and neurodegeneration</article-title>. <source>Pflugers Arch</source> (<year>2010</year>) <volume>460</volume>:<fpage>525</fpage>â<lpage>42</lpage><pub-id pub-id-type="doi">10.1007/s00424-010-0809-1</pub-id><?supplied-pmid 20229265?><pub-id pub-id-type="pmid">20229265</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkinton</surname><given-names>MS</given-names></name><name><surname>Ip</surname><given-names>JK</given-names></name><name><surname>Wood</surname><given-names>GL</given-names></name><name><surname>Crossthwaite</surname><given-names>AJ</given-names></name><name><surname>Williams</surname><given-names>RJ</given-names></name></person-group>
<article-title>Phosphatidylinositol 3-kinase is a central mediator of NMDA receptor signalling to MAP kinase (Erk1/2), Akt/PKB and CREB in striatal neurones</article-title>. <source>J Neurochem</source> (<year>2002</year>) <volume>80</volume>:<fpage>239</fpage>â<lpage>54</lpage><pub-id pub-id-type="doi">10.1046/j.0022-3042.2001.00699.x</pub-id><?supplied-pmid 11902114?><pub-id pub-id-type="pmid">11902114</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogduijn</surname><given-names>MJ</given-names></name><name><surname>Hitchcock</surname><given-names>IS</given-names></name><name><surname>Smit</surname><given-names>NP</given-names></name><name><surname>Gillbro</surname><given-names>JM</given-names></name><name><surname>Schallreuter</surname><given-names>KU</given-names></name><name><surname>Genever</surname><given-names>PG</given-names></name></person-group>
<article-title>Glutamate receptors on human melanocytes regulate the expression of MiTF</article-title>. <source>Pigment Cell Res</source> (<year>2006</year>) <volume>19</volume>:<fpage>58</fpage>â<lpage>67</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0749.2005.00284.x</pub-id><?supplied-pmid 16420247?><pub-id pub-id-type="pmid">16420247</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>C-D</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Blocking glutamate-mediated signalling inhibits human melanoma growth and migration</article-title>. <source>Exp Dermatol</source> (<year>2012</year>) <volume>21</volume>:<fpage>926</fpage>â<lpage>31</lpage><pub-id pub-id-type="doi">10.1111/exd.12048</pub-id><?supplied-pmid 23171453?><pub-id pub-id-type="pmid">23171453</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>ES</given-names></name><name><surname>Matthews</surname><given-names>JH</given-names></name><name><surname>Shaw</surname><given-names>JH</given-names></name><name><surname>Nixon</surname><given-names>J</given-names></name><name><surname>Tumewu</surname><given-names>P</given-names></name><name><surname>Finlay</surname><given-names>GJ</given-names></name><etal/></person-group>
<article-title>Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays</article-title>. <source>Eur J Cancer</source> (<year>1994</year>) <volume>30A</volume>:<fpage>1370</fpage>â<lpage>6</lpage><pub-id pub-id-type="doi">10.1016/0959-8049(94)90188-0</pub-id><?supplied-pmid 7999427?><pub-id pub-id-type="pmid">7999427</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JE</given-names></name><name><surname>Stones</surname><given-names>C</given-names></name><name><surname>Joseph</surname><given-names>W</given-names></name><name><surname>Leung</surname><given-names>E</given-names></name><name><surname>Finlay</surname><given-names>G</given-names></name><name><surname>Shelling</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines</article-title>. <source>BMC Cancer</source> (<year>2012</year>) <volume>12</volume>:<fpage>141</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-12-141</pub-id><?supplied-pmid 22475322?><pub-id pub-id-type="pmid">22475322</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>PC</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name></person-group>
<article-title>Predicting the effects of amino acid substitutions on protein function</article-title>. <source>Annu Rev Genomics Hum Genet</source> (<year>2006</year>) <volume>7</volume>:<fpage>61</fpage>â<lpage>80</lpage><pub-id pub-id-type="doi">10.1146/annurev.genom.7.080505.115630</pub-id><pub-id pub-id-type="pmid">16824020</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trevarton</surname><given-names>AJ</given-names></name><name><surname>Mann</surname><given-names>MB</given-names></name><name><surname>Knapp</surname><given-names>C</given-names></name><name><surname>Araki</surname><given-names>H</given-names></name><name><surname>Wren</surname><given-names>JD</given-names></name><name><surname>Stones-Havas</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>MelanomaDB: a web tool for integrative analysis of melanoma genomic information to identify disease-associated molecular pathways</article-title>. <source>Front Oncol</source> (<year>2013</year>) <volume>3</volume>:<fpage>184</fpage><pub-id pub-id-type="doi">10.3389/fonc.2013.00184</pub-id><pub-id pub-id-type="pmid">23875173</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Schrodinger</surname><given-names>LLC</given-names></name></person-group>
<source>The PyMOL Molecular Graphics System, Version 1.5.0.4</source> (<year>2010</year>).</mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sali</surname><given-names>A</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name></person-group>
<article-title>Comparative protein modelling by satisfaction of spatial restraints</article-title>. <source>J Mol Biol</source> (<year>1993</year>) <volume>234</volume>:<fpage>779</fpage>â<lpage>815</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1993.1626</pub-id><?supplied-pmid 8254673?><pub-id pub-id-type="pmid">8254673</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Mancusso</surname><given-names>R</given-names></name><name><surname>Gouaux</surname><given-names>E</given-names></name></person-group>
<article-title>Subunit arrangement and function in NMDA receptors</article-title>. <source>Nature</source> (<year>2005</year>) <volume>438</volume>:<fpage>185</fpage>â<lpage>92</lpage><pub-id pub-id-type="doi">10.1038/nature04089</pub-id><pub-id pub-id-type="pmid">16281028</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardingham</surname><given-names>GE</given-names></name></person-group>
<article-title>Coupling of the NMDA receptor to neuroprotective and neurodestructive events</article-title>. <source>Biochem Soc Trans</source> (<year>2009</year>) <volume>37</volume>:<fpage>1147</fpage>â<lpage>60</lpage><pub-id pub-id-type="doi">10.1042/BST0371147</pub-id><?supplied-pmid 19909238?><pub-id pub-id-type="pmid">19909238</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balch</surname><given-names>CM</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Soong</surname><given-names>SJ</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Byrd</surname><given-names>DR</given-names></name><etal/></person-group>
<article-title>Final version of 2009 AJCC melanoma staging and classification</article-title>. <source>J Clin Oncol</source> (<year>2009</year>) <volume>27</volume>:<fpage>6199</fpage>â<lpage>206</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.4799</pub-id><?supplied-pmid 19917835?><pub-id pub-id-type="pmid">19917835</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Corp</surname><given-names>IBM-</given-names></name></person-group>
<source>IBM SPSS Statistics for Windows, Version 19.0</source>. <publisher-loc>Armonk, NY</publisher-loc>: <publisher-name>IBM Corp</publisher-name> (<year>2010</year>).</mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erreger</surname><given-names>K</given-names></name><name><surname>Geballe</surname><given-names>MT</given-names></name><name><surname>Kristensen</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>PE</given-names></name><name><surname>Hansen</surname><given-names>KB</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name><etal/></person-group>
<article-title>Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-d-aspartate glutamate receptors</article-title>. <source>Mol Pharmacol</source> (<year>2007</year>) <volume>72</volume>:<fpage>907</fpage>â<lpage>20</lpage><pub-id pub-id-type="doi">10.1124/mol.107.037333</pub-id><?supplied-pmid 17622578?><pub-id pub-id-type="pmid">17622578</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauna</surname><given-names>ZE</given-names></name><name><surname>Kimchi-Sarfaty</surname><given-names>C</given-names></name></person-group>
<article-title>Understanding the contribution of synonymous mutations to human disease</article-title>. <source>Nat Rev Genet</source> (<year>2011</year>) <volume>12</volume>:<fpage>683</fpage>â<lpage>91</lpage><pub-id pub-id-type="doi">10.1038/nrg3051</pub-id><pub-id pub-id-type="pmid">21878961</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gartner</surname><given-names>JJ</given-names></name><name><surname>Parker</surname><given-names>SC</given-names></name><name><surname>Prickett</surname><given-names>TD</given-names></name><name><surname>Dutton-Regester</surname><given-names>K</given-names></name><name><surname>Stitzel</surname><given-names>ML</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><etal/></person-group>
<article-title>Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2013</year>) <volume>110</volume>(<issue>33</issue>):<fpage>13481</fpage>â<lpage>6</lpage><pub-id pub-id-type="doi">10.1073/pnas.1304227110</pub-id><pub-id pub-id-type="pmid">23901115</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prickett</surname><given-names>TD</given-names></name><name><surname>Samuels</surname><given-names>Y</given-names></name></person-group>
<article-title>Molecular pathways: dysregulated glutamatergic signaling pathways in cancer</article-title>. <source>Clin Cancer Res</source> (<year>2012</year>) <volume>18</volume>:<fpage>4240</fpage>â<lpage>6</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1217</pub-id><?supplied-pmid 22648273?><pub-id pub-id-type="pmid">22648273</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>